Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02030028 · ClinicalTrials.gov registry record · NA

ACTH Gel Therapy in Rheumatoid Arthritis

A NA study of Rheumatoid Arthritis, sponsored by Dana Ascherman.

Completed
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT02030028 is a NA study of Rheumatoid Arthritis that has completed, run by Dana Ascherman. The registered enrollment target is 18 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02030028, a NA study of Rheumatoid Arthritis, has completed, sponsored by Dana Ascherman.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate if the study drug, ACTH Gel helps decrease the disease symptoms in people with Rheumatoid Arthritis (RA) who are already taking medications prescribed by their physician and are still experiencing disease symptoms. ACTH gel has been a Food and Drug Administration-approved treatment for Rheumatoid Arthritis since 1952, and in 2010 the FDA retained RA as a disease approved for ACTH gel use. Despite its FDA approval there is very limited data on its how well ACTH gel works in improving the symptoms of people with RA.

Conditions Studied

Interventions

  • DRUG ACTHAR gel

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2014-11
Est. Completion 2022-06-30
Phase NA

Sponsor

Dana Ascherman

1 total trials

What the Registry Record Tells You About NCT02030028

The ClinicalTrials.gov registry entry for NCT02030028 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is Dana Ascherman, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which ACTHAR gel is the first listed.

NCT02030028 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02030028 about?

NCT02030028 is a clinical study titled "ACTH Gel Therapy in Rheumatoid Arthritis". The purpose of this research study is to evaluate if the study drug, ACTH Gel helps decrease the disease symptoms in people with Rheumatoid Arthritis (RA) who are already taking medications prescribed by their physician and are still experiencing disease symptoms. ACTH gel has been a Food and Drug ...

What is the current status of trial NCT02030028?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2014-11. Estimated completion is 2022-06-30.

What conditions does trial NCT02030028 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT02030028?

The interventions under investigation include: ACTHAR gel (DRUG).

Who is sponsoring clinical trial NCT02030028?

This trial is sponsored by Dana Ascherman, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02030028 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.